Share

Poordad, Fred us

List of all publications

Publishing since 2007 (Baby)

    2010

  1. Clinical Trial, Phase IIIJournal ArticleMulticenter StudyRandomized Controlled Trial Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy.  N. Engl. J. Med.  2010;362;12  Link to Rifaximin treatment in hepatic encephalopathy.
  2. Journal ArticleRandomized Controlled Trial Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.  Hepatology  2010;51;2  Link to Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
  3. Journal Article Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.  Aliment. Pharmacol. Ther.  2010;31;2  Link to Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.
  4. Journal ArticleRandomized Controlled Trial Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.  J. Viral Hepat.  2010;17;1  Link to Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

    5. 2009

  5. Clinical Trial, Phase IIJournal ArticleMulticenter StudyRandomized Controlled Trial Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.  Hepatology  2009;50;6  Link to Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.

    6. 2008

  6. Journal ArticleReview Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease.  Aliment. Pharmacol. Ther.  2008;28;5  Link to Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
  7. Journal ArticleReview Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R. Thrombocytopenia associated with chronic liver disease.  J. Hepatol.  2008;48;6  Link to Thrombocytopenia associated with chronic liver disease.
  8. Journal ArticleReview Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C.  Clin. Infect. Dis.  2008;46;1  Link to Rapid virologic response: a new milestone in the management of chronic hepatitis C.

    9. 2007

  9. Journal ArticleReview Poordad F. Review article: thrombocytopenia in chronic liver disease.  Aliment. Pharmacol. Ther.  2007;26 Suppl 1  Link to Review article: thrombocytopenia in chronic liver disease.
  10. Journal Article Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, Papadakis KA, Ippoliti A, Vasiliauskas E, Tran TT. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.  Am. J. Gastroenterol.  2007;102;11  Link to Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
  11. Journal ArticleMulticenter StudyRandomized Controlled Trial Carr C, Hollinger FB, Yoffe B, Wakil A, Phillips J, Bzowej N, Leung J, Mirro K, Poordad F, Moore DH, Gish RG. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.  Liver Int.  2007;27;8  Link to Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Back to page of Poordad, Fred.

Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.